RegenLab USA’s New R&D and Manufacturing Facility Opens in Jersey City

Medical Device Innovator Plans to Hire 150 Additional Employees

Jersey City, NJ – Choose New Jersey proudly announces that RegenLab USA, a pioneering medical device company specializing in autologous regenerative medicine and tissue engineering, has chosen Jersey City, New Jersey, for its state-of-the-art R&D and manufacturing facility, further solidifying New Jersey’s reputation as a global leader in life sciences innovation. The company celebrated the grand opening of the new research and manufacturing facility with a ribbon-cutting ceremony on Friday, June 13, 2025, at 95 Greene Street, Jersey City.

“RegenLab USA’s decision to expand in Jersey City is a testament to New Jersey’s standing as a global leader in life sciences and innovation,” said Governor Phil Murphy. “Our state offers the talent, infrastructure, and collaborative research ecosystem that pioneering companies need to grow and thrive. We are proud to welcome RegenLab USA as they invest in our communities, create high-quality jobs, and develop groundbreaking technologies that improve lives around the world.”

The facility will support advancements in aesthetics, orthopedics, gynecology, and tissue engineering, leveraging the company’s patented technology in blood component separation, backed by over 150 international patents and more than 300 scientific publications.

“The presence of multiple academic institutions in New Jersey provides invaluable collaboration opportunities for in vitro and ex vivo studies that will accelerate our research,” said Antoine Turzi, Founder & President of RegenLab USA. “We chose New Jersey because of its unmatched access to scientific talent, a thriving innovation ecosystem, and a strategic location near major metropolitan hubs. The state’s long-standing leadership in life sciences, coupled with a business-friendly environment, makes it the ideal place for RegenLab USA to grow and bring next-generation regenerative therapies to patients around the world.”

RegenLab USA’s relocation from BioBAT Brooklyn, New York, to Jersey City underscores New Jersey’s appeal as a premier life sciences hub. 

“We’re proud to welcome RegenLab USA to Jersey City, where innovation and opportunity go hand in hand,” said Jersey City Mayor Steven Fulop. “Their decision to grow here reflects the strength of our city’s talent, infrastructure, and commitment to supporting cutting-edge industries like life sciences. This expansion brings quality jobs and deepens our city’s position as a hub for medical and scientific advancement.”

RegenLab USA plans to hire 50 new employees annually, reaching approximately 200 employees over the next three years. The company’s new facility will develop and manufacture advanced medical solutions that improve patient outcomes in unmet needs of regenerative medicine.

“New Jersey’s life sciences ecosystem continues to attract cutting-edge companies like RegenLab USA,” said Wes Mathews, President & CEO of Choose New Jersey. “With access to world-class research institutions, top-tier talent, and an innovation-friendly business environment, New Jersey is the ideal home for companies at the forefront of medical advancements, and we are glad RegenLab USA is calling Jersey City home.”

“Under Governor Murphy’s leadership, New Jersey has made strategic investments in the life sciences industry, cementing our status as a global leader in the sector,” said New Jersey Economic Development Authority Chief Executive Officer Tim Sullivan. “RegenLab USA’s expansion into New Jersey underscores the strength of our innovation ecosystem, which continues to attract cutting-edge companies, create family-sustaining jobs, advance life-saving research, and drive economic growth.”

The company selected Thor Equities’ premier life sciences space in the historic Colgate-Palmolive headquarters, a prime location with proximity to New York City and Newark International Airport.

“95 Greene Street’s transformation was driven by our commitment to provide top-tier space for cutting-edge biotech companies like RegenLabs,” said Joe Sitt, Chairman of Thor Equities Group. “We’re thrilled they selected our site and are excited to support their growth and innovation.”

About Choose New Jersey

Choose New Jersey is the state’s leading non-profit business attraction organization. We harness the collective power of New Jersey’s business, government, labor, and academic sectors to expand New Jersey’s economy. We work globally, using our marketing expertise, concierge business development services, deep knowledge of the state, and convening power, in collaboration with state government, to empower businesses, entrepreneurs, leaders, and innovators to make New Jersey their home. Learn more at choosenj.com.

About RegenLab USA

RegenLab USA LLC is a leader in medical devices for autologous regenerative medicine and tissue engineering. The company’s technology is revolutionizing platelet-rich plasma (PRP) preparation and combination therapies to improve patient outcomes. RegenLab USA’s solutions are designed, manufactured, and packaged according to the highest international standards, including ISO 13485, EU-MDR 2017/745, and MDSAP. For more information, visit regenlabusa.com.